PF-03882845

Phase 1Small molecule

Pfizer

PF-03882845 is one of 42 small molecule programs targeting Diabetic Nephropathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic NephropathyActive, not recruiting

Diabetic NephropathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

132 competitors in Diabetic Nephropathy

#DrugCompanyPhaseTrials

Tracleer

Johnson & Johnson

Phase 3

1 2

Cialis

Eli Lilly

Phase 3

1 3

Daliresp

AstraZeneca

Phase 3

1 4

Vanrafia

Novartis

Phase 3

1 5

Niclocide

Bayer

Phase 3

1 6

Niacor

AbbVie

Phase 3

1 7

Cysteine Hydrochloride

Novartis

Phase 3

1 8

Reata

Biogen

Phase 3

—9

Benicar

CCosette Pharmaceuticals, Inc.

Phase 3

3 10

Invokana

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Nephropathy1 trial

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

Terminated· Pfizer logo

Pfizer·Phase 1·NCT01488877·6 enrolled

Absorption1 trial

A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption

Completed· Pfizer logo

Pfizer·Phase 1·NCT01366287·12 enrolled

Single Dose1 trial

A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT01314898·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PF-03882845. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-03882845 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-03882845. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Pfizer

PF-03882845

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Nephropathy1 trial

Absorption1 trial

Single Dose1 trial

References

Drug Info

Quick Facts

Related News